Daiwa Securities Group Inc. continued to hold its position in Alkermes PLC (NASDAQ:ALKS) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,400 shares of the company’s stock at the end of the second quarter. Daiwa Securities Group Inc.’s holdings in Alkermes PLC were worth $147,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of ALKS. S&CO Inc. raised its position in shares of Alkermes PLC by 4.3% in the second quarter. S&CO Inc. now owns 9,800 shares of the company’s stock worth $424,000 after buying an additional 400 shares during the period. LS Investment Advisors LLC raised its position in shares of Alkermes PLC by 23.6% in the second quarter. LS Investment Advisors LLC now owns 2,846 shares of the company’s stock worth $123,000 after buying an additional 544 shares during the period. IBM Retirement Fund raised its position in shares of Alkermes PLC by 1.2% in the second quarter. IBM Retirement Fund now owns 15,193 shares of the company’s stock worth $657,000 after buying an additional 177 shares during the period. Fox Run Management L.L.C. acquired a new position in shares of Alkermes PLC during the second quarter worth $264,000. Finally, Independent Portfolio Consultants Inc. acquired a new position in shares of Alkermes PLC during the second quarter worth $179,000. 95.13% of the stock is owned by hedge funds and other institutional investors.
Shares of Alkermes PLC (NASDAQ:ALKS) traded up 1.11% on Friday, hitting $45.71. The company had a trading volume of 696,444 shares. Alkermes PLC has a 52 week low of $27.14 and a 52 week high of $80.71. The stock’s 50-day moving average is $46.88 and its 200 day moving average is $43.84. The company’s market capitalization is $6.93 billion.
Alkermes PLC (NASDAQ:ALKS) last issued its quarterly earnings data on Thursday, July 28th. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.09. Alkermes PLC had a negative return on equity of 14.18% and a negative net margin of 41.19%. The company had revenue of $195.20 million for the quarter, compared to the consensus estimate of $174.15 million. During the same quarter last year, the company earned ($0.09) earnings per share. The firm’s revenue for the quarter was up 28.9% compared to the same quarter last year. Equities analysts expect that Alkermes PLC will post ($0.12) EPS for the current year.
A number of brokerages have weighed in on ALKS. Leerink Swann began coverage on Alkermes PLC in a research report on Tuesday. They issued an “outperform” rating and a $57.00 target price for the company. Citigroup Inc. boosted their target price on Alkermes PLC from $44.00 to $53.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 27th. Zacks Investment Research lowered Alkermes PLC from a “buy” rating to a “hold” rating in a research report on Tuesday, September 27th. Cowen and Company reissued a “buy” rating on shares of Alkermes PLC in a research report on Friday, September 23rd. Finally, Morgan Stanley reissued a “sell” rating and issued a $41.00 target price on shares of Alkermes PLC in a research report on Friday, September 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $55.90.
In other Alkermes PLC news, CAO Iain Michael Brown sold 29,976 shares of the firm’s stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $45.92, for a total value of $1,376,497.92. Following the completion of the sale, the chief accounting officer now owns 25,696 shares of the company’s stock, valued at $1,179,960.32. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP David Joseph Gaffin sold 2,382 shares of the firm’s stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $45.92, for a total value of $109,381.44. Following the completion of the sale, the senior vice president now directly owns 22,816 shares of the company’s stock, valued at approximately $1,047,710.72. The disclosure for this sale can be found here. 4.75% of the stock is owned by company insiders.
Alkermes PLC Company Profile
Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis.
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.